Open an account

Aquestive Therapeutics

AQST · NASDAQ

$4.05+$0.22 (+5.74%)TodayMarket closed ·
Prev close $3.83

About AQST

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 147 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Employees
147
Headquarters
WARREN, New Jersey
Listed
Jul 25, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
aquestive.com

AQST key statistics

Market cap
508.32M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.33M
Volume
2.26M
Open price
$3.83
High today
$4.13
Low today
$3.79
52 Week high
$7.55
52 Week low
$2.93

Aquestive Therapeutics (AQST) at a glance

Aquestive Therapeutics (AQST) last traded at $4.05, with a market cap of 508.32M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.79 and $4.13. The current price is 6.9% above the day's low and 1.9% below its high.

Volume so far is 2.26M shares, in line with the average of 2.33M shares a day.

Over the past year Aquestive Therapeutics has ranged from $2.93 to $7.55, and now sits 24% of the way up that range.

Aquestive Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.08 per share against an estimate of -$0.1054.

The average analyst price target is $9.52, 135.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $9.52
Low
$6.06
Now
$4.05
High
$11.55

AQST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 30.8% on average.

  1. Q3 FY24: reported -$0.13 per share against an estimate of -$0.1292
  2. Q4 FY24: reported -$0.19 per share against an estimate of -$0.1384
  3. Q1 FY25: reported -$0.24 per share against an estimate of -$0.1734
  4. Q2 FY25: reported -$0.14 per share against an estimate of -$0.1717
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1352
  6. Q4 FY25: reported -$0.15 per share against an estimate of -$0.1352
  7. Q1 FY26: reported -$0.07 per share against an estimate of -$0.1399
  8. Q2 FY26: reported -$0.08 per share against an estimate of -$0.1054

AQST news

  • Vandana Singh

    Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug

  • Press releasePRNewswire

    Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop

  • Vandana Singh

    Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

  • Vandana Singh

    Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

  • Press releaseGlobe Newswire

    AQUESTIVE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff Role

  • Press releaseGlobe Newswire

    The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 4, 2026 in Aquestive Therapeutics, Inc. Lawsuit - AQST

Similar companies

Companies in the same industry as Aquestive Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.